Simulations Plus, Inc. (SLP) EPS Estimated At $0.11

March 15, 2018 - By Marguerite Chambers

 Simulations Plus, Inc. (SLP) EPS Estimated At $0.11
Investors sentiment increased to 2.06 in Q3 2017. Its up 0.54, from 1.52 in 2017Q2. It increased, as 1 investors sold Simulations Plus, Inc. shares while 17 reduced holdings. 16 funds opened positions while 21 raised stakes. 5.43 million shares or 5.64% more from 5.14 million shares in 2017Q2 were reported.
Moreover, Bahl Gaynor has 0.01% invested in Simulations Plus, Inc. (NASDAQ:SLP). Skylands Cap Limited Liability Corporation has 122,950 shares for 0.25% of their portfolio. 10,724 were accumulated by Telos Cap Mgmt. Wedge Cap Mngmt L Ltd Partnership Nc holds 0.01% or 47,100 shares. 28,324 are owned by Redmond Asset Management Lc. North Star Invest owns 123,550 shares. Tiaa Cref Investment Mngmt Ltd Limited Liability Company holds 0% or 26,455 shares in its portfolio. Granite Investment Prtn Ltd Llc has 146,519 shares. Bessemer Gru holds 0% or 29,700 shares in its portfolio. Connors Investor Inc stated it has 31,957 shares. Bank Of Ny Mellon has invested 0% of its portfolio in Simulations Plus, Inc. (NASDAQ:SLP). Stanley accumulated 0.32% or 77,364 shares. Strs Ohio holds 0% in Simulations Plus, Inc. (NASDAQ:SLP) or 3,200 shares. Legal And General Grp Pcl holds 1,570 shares. State Common Retirement Fund holds 11,600 shares.

Since September 27, 2017, it had 0 buys, and 3 insider sales for $887,166 activity.

Analysts expect Simulations Plus, Inc. (NASDAQ:SLP) to report $0.11 EPS on April, 9.They anticipate $0.04 EPS change or 57.14 % from last quarter’s $0.07 EPS. SLP’s profit would be $1.90 million giving it 36.93 P/E if the $0.11 EPS is correct. After having $0.10 EPS previously, Simulations Plus, Inc.’s analysts see 10.00 % EPS growth. The stock increased 1.56% or $0.25 during the last trading session, reaching $16.25. About 28,972 shares traded. Simulations Plus, Inc. (NASDAQ:SLP) has risen 48.65% since March 15, 2017 and is uptrending. It has outperformed by 31.95% the S&P500.

Simulations Plus, Inc. develops and sells drug discovery and development software for mechanistic modeling and simulation. The company has market cap of $281.01 million. The firm offers GastroPlus, which simulates the absorption, pharmacokinetics , and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments. It has a 46.43 P/E ratio. It also provides PKPlus, a standalone program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for NCA and compartmental PK modelling; ADMET Predictor, a chemistry computer program, which takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher that integrates with MedChem Studio and ADMET Predictor.

More notable recent Simulations Plus, Inc. (NASDAQ:SLP) news were published by: which released: “Simulations Plus Announces Senior Management Changes” on August 31, 2017, also with their article: “DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym” published on August 08, 2017, published: “DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym® Version 7A” on January 11, 2018. More interesting news about Simulations Plus, Inc. (NASDAQ:SLP) were released by: and their article: “Simulations Plus’ (SLP) CEO Walt Woltosz on Q4 2017 Results – Earnings Call …” published on November 15, 2017 as well as‘s news article titled: “Simulations Plus, Inc. (SLP) Ex-Dividend Date Scheduled for November 10, 2017” with publication date: November 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.